EUCTR2010-022802-41-EE进行中（未招募）不适用
SAFETY AND PHARMACOKINETICS OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, MULTIPLE DOSE ESCALATION STUDY WITH A RANDOMISED PHASE II EXPANSION COMPONENT - Arades Phase I/II
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Written informed consent (IC) obtained.
- •2.Male patients aged 18 years or older.
- •3.Histologically confirmed adenocarcinoma of prostate.
- •4.Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral orchiectomy and serum testosterone level < 50 ng/dl (< 0.5 ng/ml, < 1.7 nmol/l) at screening.
- •5.Progressive metastatic disease during the androgen deprivation, and after the treatment with antiandrogen and antiandrogen withdrawal, demonstrated by 1 or more of the following criteria:
- •patients with measurable or non-measurable disease (i.e. no target lesions), progression defined by a new soft tissue lesion or rising PSA value over 2 ng/ml in at least 2 rising successive measurements, at least 1 week apart. If the confirmatory PSA value is less than the screening PSA value, then an additional test for the rising PSA is required to document progression.
- •patients with measurable disease, progression defined by RECIST 1.1 criteria.
- •patients with metastatic bone disease, progression defined by 2 or more new lesions in a radionuclide bone scan.
- •6.The patient:
- •has received 1 or 2 chemotherapy treatments, or
- •is ineligible for chemotherapy, or
- •is intolerant of chemotherapy, or
- •has declined chemotherapy, or
- •has no need for chemotherapy yet.
- •7.The patient has ECOG performance status of 0-1 at screening.
- •8.The patient has at screening blood counts:
- •absolute neutrophil count = 1.5 x 109/l),
- •thrombocytes = 100 x 109/l),
- •haemoglobin = 10 g/dl (can be post-transfusion).
- •9.The patient has at screening liver, renal and albumin values of:
- •alanine aminotransferase (ALT) or aspartate transaminase (AST) = 2.5 x upper limit of normal (ULN),
- •total bilirubin = 2 x ULN,
- •creatinine = 1.5 x ULN,
- •albumin > 3.0 g/dl
- •10.Prior treatment with antiandrogen. Discontinuation of bicalutamide or nilutamide at least 6 weeks and other antiandrogens at least 4 weeks prior to the start of the study treatment.
- •11.Life expectancy of at least 3 months.
- •12.Sexually active patients must agree to use condoms as an effective barrier method during the study treatment and for 3 months after the end of the treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 65
排除标准
- •1.Known hypersensitivity to the study treatment formulation excipients.
- •2.The patient has received prior therapy with MDV3100 or any investigational AR antagonist.
- •3.The patient has received chemotherapy, radiotherapy or any experimental therapy within 4 weeks (within 6 weeks for nitrosoureas and mitomycin C) of the start of the study treatment or has not recovered to grade = 1 or returned to baseline from any acute treatment-related toxicities of the previous therapy except for alopecia and grade 2 neuropathy.
- •4.Initiation of bisphosphonate therapy within 4 weeks prior to the start of the study treatment. Patients on a stable dose of bisphosphonate for at least for 30 days prior to the start of the study treatment can continue the treatment during the study.
- •5.Therapy with estrogen within 30 days prior the start of the study treatment. 6.Therapy with oral ketoconazole or CYP17 inhibitor within 30 days prior to the start of the study treatment.
- •7.Use of systemic corticosteroid with dose greater than the equivalent of 10 mg of prednisone/day within 30 days prior to the start of the study treatment. Patients on a stable maintenance dose of corticosteroid = 10 mg/day can continue the treatment during the study.
- •8.Prior use of any herbal products known to decrease PSA levels (e.g. PC-SPES or saw palmetto) within 30 days prior the start of the study treatment.
- •9.Known metastases in the brain.
- •10.History of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
- •11.Major surgery within 4 weeks prior to the start of the study treatment. 12.Serious persistent infection within 14 days prior to the start of the study treatment.
- •13.Known gastrointestinal disease or procedure that affects the absorption of the study treatment.
- •14.Serious concurrent medical condition or psychiatric illness.
- •15.History of congestive heart failure New York heart association (NYHA) class III or IV or uncontrolled hypertension at screening.
- •16.History or family history of long QTc syndrome.
- •17.Abnormalities in centrally read 12-lead ECG considered by the investigator to be clinically significant or PR interval > 200 ms or prolongation or shortening of the rate-corrected (Fridericia) QT interval (repeated demonstration of QTc interval > 450 ms or < 300 ms) at screening.
- •18.The patient has received any investigational treatment within 30 days prior to the start of the study treatment.
- •19.Known history of hepatitis B, or hepatitis C.
- •20.Any condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures.
- •21.The patient is not able to swallow the study treatment capsules.
研究者
相似试验
进行中（未招募）
不适用
SAFETY, ABSORPTION AND DISTRIBUTION OF ODM-201 IN PATIENTS WITH PROSTATE CANCER:EUCTR2010-022802-41-FIOrion Corporation Orion Pharma130
进行中（未招募）
1 期
SAFETY, ABSORPTION AND DISTRIBUTION OF ODM-201 IN PATIENTS WITH PROSTATE CANCER:Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer)MedDRA version: 14.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022802-41-GBOrion Corporation Orion Pharma
进行中（未招募）
不适用
SAFETY, ABSORPTION AND DISTRIBUTION OF ODM-201 IN PATIENTS WITH PROSTATE CANCER:EUCTR2010-022802-41-CZOrion Corporation Orion Pharma130
进行中（未招募）
1 期
Safety and pharmacokinetics of ODM-204 in patients with metastatic castration -resistant prostate cancer: an open-label,non - randomised, uncontrolled, multicentre, dose escalation, first-in-man study with additional expansion phase with a dose selected in the escalation phaseMetastatic castration resistant prostate cancer (mCRPC)MedDRA version: 18.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003642-26-GBOrion Corporation Orion Pharma23
进行中（未招募）
1 期
Safety and pharmacokinetics of ODM-204 in patients with metastatic castration -resistant prostate cancer: an open-label, non - randomised, uncontrolled, multicentre, dose escalation, first-in- man study with additional expansion phase with a dose selected in the escalation phaseMetastatic castration resistant prostate cancer (mCRPC)MedDRA version: 18.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1 Level: LLT Classification code 10036916 Term: Prostate cancer stage D System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003642-26-FIOrion Corporation Orion Pharma95